Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by Wino115on Dec 09, 2024 1:30pm
116 Views
Post# 36353070

RE:RE:My take so far...

RE:RE:My take so far...I think Ionis is focused elsewhere and has a very lengthy pipeline and 5 existing drugs. Doesn't seem likely but who knows?   

On these results, decent but not powered enough to reach any conclusions - just more data to add. It does look like they understand the safety issues better with lower dosage more frequently being tolerable.  Now, how high can you go is the open question.  Second is that the actual delivery mechanism and the secondary and tertiary MOAs seem to be showing in the marker analysis, which is good.  In other words, their theory around how the toxin gets in and what it does was not counter-acted --it appears to be doing some of that around the stem cells and vasculogenic mimicry. 

They really needed more time to give more doses, this was rather short.  Needed more patients, etc... 

I seem to recall they had the option to add 4-5 more people in the last leg and had the money for that budgeted.  Is that what they're saying around doing slightly higher dosage with another small group of 4-5?  Hard to really tell form the wording, or is that what they will seek initial financing and. partnering for --something small like that, get to know the partner, then depending on results, move to a proper Phase 2 to get efficacy optimized.  This is novel --first of it's kind PDC, unique biomarker, lots of data around what it's doing.  I have to think someone will want to try to see if they can boost efficacy. It may not be one of the big drug companies, and it may even be one of the larger overseas names who has an ADC franchise or oncology.  The announcement of a partner will be the big even and hopefully they find one or find a financing partner - either one.  They've moved the ball a fair way down the field and have a ton of data now.  I would like to see them collate all this, publish it, do another 5 patients with the higher dose (if FDA allows) and add that to the mix.   It's also too bad they couldn't keep those patients on dosage for another few weeks and see if they shrink >30% (Maybe they are?).     But the point made above, that these are patients near death that tried everything and it failed, yet this has shown SD with some better results, is still a very good start for a new oncology drug. 


<< Previous
Bullboard Posts
Next >>